All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Lymphoma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.

The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. View funders.

2016-11-17T15:27:49.000Z

Challenges in defining a new standard of care in Primary CNS Lymphoma

Nov 17, 2016
Share:

Bookmark this article

In May 2016, Glass et al. published in the Journal of Clinical Oncology the results of a phase I/II study into the efficacy of methotrexate, temozolomide (TMZ) with rituximab, proceeded by hyperfractionated Whole-Brain Radiotherapy (hWBRT) in patients with Primary CNS Lymphoma (PCNSL), followed by maintenance treatment with TMZ. The reported 2-year OS and PFS were 80.8% and 63.6%, respectively.

In a more recent correspondence, also in the Journal of Clinical Oncology, Marc C. Chamberlain, of the University of Washington and Fred Hutchinson Cancer Research Center, Seattle, responded to these results explaining potential issues with the study. The key points of concern were:

  • Due to timing of assessments, it was unclear if rituximab, dosed at 5 intervals alongside HD-MTX, provided an additional benefit
  • TMZ has limited data as a single-agent treatment in this setting
  • TMZ dose was lower than other studies, potentially leading to undertreatment with TMZ
  • Use of dose-reduced hWBRT to reduce late neurotoxicity, however no significant evidence of late neurotoxicity was reported since the measure of cognitive dysfunction used was poor
  • Myeloablative conditioning chemotherapy and ASCT are more frequently being suggested as alternatives to consolidation WBRT
  • Value of 10 cycles of TMZ maintenance therapy, following hWBRT, was not shown


In conclusion, both the authors of the original study and Marc Chamberlain state that randomized trials are needed to elucidate the value of these protocol modifications for treatment of PCNSL. Marc Chamberlain also suggested that deciding upon which regimen a patient should follow is based on “interpretation of a confusing literature”, and the physician’s familiarity with and subjective opinions of therapies, amplifying the need for more randomized, multi-arm studies.

  1. Chamberlain M.C. Immunochemotherapy, the New Standard of Care for Primary CNS Lymphoma: However, Which One? Journal of Clinical Oncology. 2016 Oct; 34(33):4056–4057. doi: 10.1200/JCO.2016.68.9018.
  2. Glass J. et al. Phase I and II Study of Induction Chemotherapy With Methotrexate, Rituximab, and Temozolomide, Followed By Whole-Brain Radiotherapy and Postirradiation Temozolomide for Primary CNS Lymphoma: NRG Oncology RTOG 0227. Journal of Clinical Oncology. 2016 May; 34(14):1620–5. doi: 10.1200/JCO.2015.64.

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Your opinion matters

HCPs, what is your preferred format for educational content on the Lymphoma Hub?
27 votes - 2 days left ...

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox